Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Increased expression of PD‑L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: D. A. Spandidos Country of Publication: Greece NLM ID: 101475259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-3004 (Electronic) Linking ISSN: 17912997 NLM ISO Abbreviation: Mol Med Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: Athens, Greece : D. A. Spandidos
    • Subject Terms:
      Gene Expression Regulation, Neoplastic* ; Immunomodulation*; B7-H1 Antigen/*genetics ; Neoplasms/*etiology ; Neoplasms/*metabolism ; Papillomavirus E7 Proteins/*metabolism; Biomarkers, Tumor ; Cell Line, Tumor ; Cytotoxicity, Immunologic ; Female ; Gene Expression ; Human papillomavirus 16/genetics ; Humans ; Immunohistochemistry ; Lymphocyte Activation ; Oncogene Proteins, Viral/genetics ; Oncogene Proteins, Viral/metabolism ; Papillomavirus E7 Proteins/genetics ; T-Lymphocyte Subsets/immunology ; T-Lymphocyte Subsets/metabolism ; Uterine Cervical Neoplasms/etiology ; Uterine Cervical Neoplasms/metabolism
    • Abstract:
      Cytotoxic T lymphocyte dysfunction is frequently associated with PD‑L1/PD‑1 pathway activation, and is a principal obstacle in cancer therapy. In the present study, the mechanisms underlying the human papillomavirus (HPV)‑induced evasion of cervical cancer cells to the host immune system via the programmed death ligand  1/programmed death 1 (PD‑L1/PD‑1) signaling pathway was investigated. A significant increase in the expression of the HPV16E7 viral protein and PD‑L1 in cervical tissues was observed when compared with normal cervical tissues. In addition, a positive correlation between HPV16E7 and PD‑L1 expression was observed by immunohistochemical staining and reverse transcription‑polymerase chain reaction. Overexpressing HPV16E7 oncoprotein in the epithelial carcinoma of PC3 cells increased the expression level of the PD‑L1 protein and inhibited peripheral blood mononuclear cell (PBMC) proliferation and cytotoxic T lymphocyte (CTL) activity. Upon knockdown of HPV16E7 in HPV16‑associated CaSki cervical cancer cells with a relevant siRNA, a reduction in PD‑L1 protein expression was observed, as well as a significant increase in PBMC proliferation and CTL activity. A recombinant plasmid, MSCVPIG‑soluble PD‑1, was constructed and transfected into the CaSki cell line, and was co‑cultured with PBMCs. PBMC proliferation and CTL activity were observed to increase significantly. In conclusion, the results presented in the current study suggest that overexpression of PD‑L1, induced by HPV16E7, may be responsible for lymphocyte dysfunction. In addition, soluble PD‑1 may restore the function of tumor‑infiltrating lymphocytes by inhibiting the PD‑L1/PD‑1 signaling pathway. These results may provide a novel insight for immunotherapeutic approaches in the treatment of cervical cancer.
    • References:
      Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5271-9. (PMID: 17875755)
      Head Neck Pathol. 2013 Jun;7(2):113-21. (PMID: 23179191)
      J Virol. 2012 Jun;86(11):6358-64. (PMID: 22457518)
      Cancer Res. 2013 Jan 1;73(1):128-38. (PMID: 23135914)
      Yale J Biol Med. 2011 Dec;84(4):409-21. (PMID: 22180678)
      J Immunol. 2003 Apr 1;170(7):3637-44. (PMID: 12646628)
      CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. (PMID: 15761078)
      J Exp Med. 2006 Apr 17;203(4):883-95. (PMID: 16606670)
      Ann N Y Acad Sci. 2011 Jan;1217:45-59. (PMID: 21276005)
      J Virol Methods. 2014 Sep;206:12-8. (PMID: 24880067)
      Nat Med. 2004 Sep;10(9):909-15. (PMID: 15340416)
      Nature. 2006 Feb 9;439(7077):682-7. (PMID: 16382236)
      J Virol. 2001 May;75(9):4283-96. (PMID: 11287578)
      Virology. 2014 Aug;462-463:14-24. (PMID: 25092457)
      Cancer. 2010 Apr 1;116(7):1757-66. (PMID: 20143437)
      Nat Rev Cancer. 2003 Sep;3(9):666-75. (PMID: 12951585)
      Br J Cancer. 1997;76(10):1353-60. (PMID: 9374383)
      Science. 1989 Feb 17;243(4893):934-7. (PMID: 2537532)
      Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25. (PMID: 16949997)
      Cell. 1990 Dec 21;63(6):1129-36. (PMID: 2175676)
      J Clin Virol. 2000 Oct;19(1-2):1-5. (PMID: 11091143)
      Nat Med. 2002 Aug;8(8):793-800. (PMID: 12091876)
      J Clin Oncol. 2015 Jun 10;33(17 ):1974-82. (PMID: 25605845)
      Cancer Res. 2013 Mar 15;73(6):1733-41. (PMID: 23288508)
      J Virol. 2000 May;74(9):4174-82. (PMID: 10756030)
      Indian J Med Res. 2009 Sep;130(3):266-76. (PMID: 19901436)
    • Accession Number:
      0 (B7-H1 Antigen)
      0 (Biomarkers, Tumor)
      0 (Oncogene Proteins, Viral)
      0 (Papillomavirus E7 Proteins)
      0 (oncogene protein E7, Human papillomavirus type 16)
    • Publication Date:
      Date Created: 20170112 Date Completed: 20170509 Latest Revision: 20181113
    • Publication Date:
      20221213
    • Accession Number:
      PMC5367331
    • Accession Number:
      10.3892/mmr.2017.6102
    • Accession Number:
      28075442